<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02386774</url>
  </required_header>
  <id_info>
    <org_study_id>1208180</org_study_id>
    <secondary_id>2015-A00331-48</secondary_id>
    <nct_id>NCT02386774</nct_id>
  </id_info>
  <brief_title>Innovative Imaging of the Conjunctiva, Cornea, and Ocular Adnexa</brief_title>
  <acronym>INNOV-EYE</acronym>
  <official_title>Innovative Imaging of the Conjunctiva, Cornea, and Ocular Adnexa : Study of a Handheld in Vivo Confocal Microscope and of a Fluorescent in Vivo Confocal Microscope</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In vivo confocal microscopy (IVCM) used in tertiary care ophthalmology centers is performed
      with two reflectance microscopes attached on a mounting with limited movement along the XYZ
      axes. Consequently, ocular diseases in the central area have been described (mostly cornea
      and adjacent conjunctiva). Two dermatology IVCM (an handheld small IVCM and a
      multifluorescent one) present significant innovations that the investigators want to assess
      in ophthalmology for the diagnosis of conjunctiva, cornea, eyelid and lachrymal tract
      diseases. The handheld IVCM have unlimited degrees of freedom and a small diameter objective.
      It could dramatically increase the area accessible to IVCM (whole conjunctiva, eyelids,
      proximal lachrymal tract) (part 1 of the present study). The fluorescent IVCM allows the use
      of a wide range of fluorescent markers liable to increase the specificity of the diagnosis by
      revealing staining patterns corresponding to a specific disease and not to others (part 2 of
      the study)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 21, 2016</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic performance (sensitivity (se) and specificity (sp)) of the handheld IVCM in ocular surface and adnexa diseases</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>handheld IVCM : sensitivity (se) and specificity (sp) in each 8 subgroups of diseases</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>handheld IVCM : positive and negative predictive values in each 8 subgroups of diseases</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>handheld IVCM : AUC of the ROC curve in each 8 subgroups of diseases</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>handheld IVCM : factors influencing image quality</measure>
    <time_frame>1 year</time_frame>
    <description>using a scale to 3 levels (2 : optic diagnosis ; 1 : presence of artifacts but possible optic diagnosis ; 0 :impossible optic diagnosis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>handheld IVCM : determining the limits of the tumor</measure>
    <time_frame>1 year</time_frame>
    <description>(in the particular case of tumors requiring surgery)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fluorescence : staining patterns obtained for each disease group</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fluorescence : characteristics of the micro-angiography</measure>
    <time_frame>1 year</time_frame>
    <description>characteristics of the conjunctival vessels in normal and diabetic patients</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Corneal Disease</condition>
  <condition>Blepharitis</condition>
  <condition>Lacrimal Apparatus Diseases</condition>
  <arm_group>
    <arm_group_label>an ocular or ocular adnexa disease</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patient presenting with an ocular or ocular adnexa disease in the Dermatology or Ophthalmology ward.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>diabetic patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Handheld IVCM Vivascope 3000 (Caliber/Mavig) anesthesic eyedrop : oxybuprocaïne Thea 1,6 mg/0,4 ml</intervention_name>
    <description>used anesthesic eyedrop : oxybuprocaïne Thea 1,6 mg/0,4 ml</description>
    <arm_group_label>an ocular or ocular adnexa disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Multifluorescence IVCM vivascope 1500 ML (Caliber/Mavig)</intervention_name>
    <description>used for Multifluorescence IVCM
anesthesic eyedrop : oxybuprocaïne (1,6 mg/0,4 ml)
Fluorescein 0,5%, Rose Bengal , Infracyanine</description>
    <arm_group_label>an ocular or ocular adnexa disease</arm_group_label>
    <arm_group_label>diabetic patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>microangiography</intervention_name>
    <description>realization of the microangiography with intravenous injection of fluoresceine and indocyanine green.</description>
    <arm_group_label>an ocular or ocular adnexa disease</arm_group_label>
    <arm_group_label>diabetic patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presenting with an ocular or ocular adnexa disease (infectious keratitis, stromal
             dystrophy, corneal surgery, ocular surface toxicity of eyedrops, cornea-conjunctival
             tumors, chronic blepharitis, eyelid tumors, diseases of the proximal lachrymal tract).

          -  For the microangiography: diabetic patients

        Exclusion Criteria:

          -  Allergy to one of the 3 dyes (fluorescein, indocyanine green, rose Bengal)

          -  Pregnancy and breast feeding

          -  Predicable impossible follow up

          -  For patient volunteer for intravenous injections: beta blockers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilles THURET, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de St Etienne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilles THURET, MD PhD</last_name>
    <phone>04 77 12 75 40</phone>
    <phone_ext>+33</phone_ext>
    <email>gilles.thuret@univ-st-etienne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carine LABRUYERE</last_name>
    <phone>04 77 12 04 69</phone>
    <phone_ext>+33</phone_ext>
    <email>carine.labruyere@chu-st-etienne.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chu de Saint Etienne</name>
      <address>
        <city>Saint Etienne</city>
        <state>Dermatology</state>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jean Luc PERROT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bruno LABEILLE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elisa CINOTTI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frederic CAMBAZARD, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu de Saint Etienne</name>
      <address>
        <city>Saint Etienne</city>
        <state>Ophtalmology</state>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Philippe GAIN, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Damien GRIVET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gilles THURET, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2015</study_first_submitted>
  <study_first_submitted_qc>March 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2015</study_first_posted>
  <last_update_submitted>February 15, 2018</last_update_submitted>
  <last_update_submitted_qc>February 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>In vivo confocal microscopy</keyword>
  <keyword>corneal disease</keyword>
  <keyword>Blepharitis</keyword>
  <keyword>Lacrimal Apparatus Diseases</keyword>
  <keyword>Microscopy, Confocal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blepharitis</mesh_term>
    <mesh_term>Corneal Diseases</mesh_term>
    <mesh_term>Lacrimal Apparatus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Tetrahydrozoline</mesh_term>
    <mesh_term>Benoxinate</mesh_term>
    <mesh_term>Procaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

